Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19330747 | 0.83 | MEN1 (0.41) | KMT2AMEN1CA1CA2ALDH1A1 | |
| SCHEMBL11626605 | 0.79 | MEN1 (0.64) | KMT2AMEN1CA1CA2CRHBP | |
| SCHEMBL19932031 | 0.76 | MEN1 (0.37) | KMT2AMEN1ALDH1A1POLBMAPK1 | |
| SCHEMBL3345839 | 0.74 | CA1 (0.59) | KMT2AMEN1CA1CA2ALDH1A1 | |
| SCHEMBL29729025 | 0.74 | CA1 (0.59) | KMT2AMEN1CA1CA2ALDH1A1 | |
| SCHEMBL18182085 | 0.74 | CA1 (0.41) | KMT2AMEN1CA1CA2CRHBP | |
| SCHEMBL18984664 | 0.74 | MEN1 (0.34) | KMT2AMEN1CA1CA2 | |
| SCHEMBL11626560 | 0.74 | ALDH1A1 (0.49) | KMT2AMEN1CRHBPCRHR2ALDH1A1 | |
| SCHEMBL29442687 | 0.73 | CTRC (0.47) | KMT2AMEN1ALDH1A1TRIM24TRIM33 | |
| SCHEMBL836449 | 0.73 | CTRC (0.47) | KMT2AMEN1ALDH1A1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612188-B1 | HETEROBIVALENT LIGANDS SUITABLE FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | T C ISTANBUL MEDIPOL UNIV (TR) | 2023-12-13 | — | — | EP | disclosed |
| US-11053270-B2 | Heterobivalent ligands suitable for use in the treatment of Parkinson's disease | T C ISTANBUL MEDIPOL UENIVERSITESI (TR) | 2021-07-06 | — | — | US | disclosed |
| US-20210147421-A1 | HETEROBIVALENT LIGANDS SUITABLE FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | T C ISTANBUL MEDIPOL UENIVERSITESI (TR) | 2021-05-20 | — | — | US | disclosed |
| WO-2019004970-A2 | HETEROBIVALENT LIGANDS SUITABLE FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | T.C. İSTANBUL MEDİPOL ÜNİVERSİTESİ (TR) | 2019-01-03 | — | — | WO | disclosed |
| US-8378118-B2 | Pyrazole-based thyroid receptor compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2013-02-19 | — | — | US | disclosed |
| US-20120202816-A1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS, LTD. (IN) | 2012-08-09 | — | — | US | disclosed |
| US-8143424-B2 | Thyroid like compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2012-03-27 | — | — | US | disclosed |
| EP-2061766-B1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD (IN) | 2010-08-18 | — | — | EP | disclosed |
| US-20100168110-A1 | Novel Compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-07-01 | — | — | US | disclosed |
| EP-2061766-A2 | NOVEL COMPOUNDS | Torrent Pharmaceuticals Ltd (IN) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008149379-A2 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD. (IN) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202816-A1 | NOVEL COMPOUNDS | TSHR, THRB, GPR119 | KMT2A 3000/4885MEN1 541/4885CA1 4259/4885 |
| US-20210147421-A1 | HETEROBIVALENT LIGANDS SUITABLE FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | PARK7, SNCA, NLN | KMT2A 3594/4885MEN1 4697/4885CA1 3491/4885 |
| US-11053270-B2 | Heterobivalent ligands suitable for use in the treatment of Parkinson's disease | PARK7, SNCA, NLN | KMT2A 3594/4885MEN1 4697/4885CA1 3491/4885 |
| US-20100168110-A1 | Novel Compounds | TSHR, THRB, GPR119 | KMT2A 3000/4885MEN1 541/4885CA1 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.